Women’s Health currently receives insufficient recognition from both policymakers and regulators. This is evident in the inadequate funding allocated to researchers and entrepreneurs in the field, resulting in a limited understanding of the underlying pathophysiological processes of related diseases. There’s a pressing need for increased incentives on the regulatory front, similar to those granted to orphan diseases.
While the FDA and EMA review and approve novel pharmaceuticals and medical devices, these agencies function solely as regulatory bodies, adhering to decisions made by healthcare policymakers (the US Congress and the European Commission, respectively).
Although they consult policy making, they lack the autonomy to offer incentives independently. Therefore, it becomes imperative to raise policymakers’ awareness about the current state of Women’s Health and the areas that require enhancement.